Glimepiride is an antidiabetic agent used for lowering blood glucose levels. It induces the activity of peroxisome proliferator-activated receptor-gamma (PPAR gamma). It lowers blood glucose levels by binding to ATP-sensitive potassium channel receptors on the surface of pancreatic cells. The purpose of this study was to perform a comparative analysis of different physicochemical parameters (weight variation, hardness, thickness, friability, disintegration time, and dissolution time) of 3 different commercially available brands of glimepiride in the market. Statistical analysis revealed minor variations in the results. It was found that GETRYL showed the highest % dissolution among all the 3 brands whereas AMARYL took the least time to disi...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharm...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
Glimepiride is an antidiabetic agent used for lowering blood glucose levels. It induces the activity...
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator ...
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator ...
Background: Glimepiride (HOE490, AmarylR) is a new, third generation sulfonylurea, which binds to a ...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background: Diabetes mellitus is a major public health problem with many complications. The Global B...
Objective: To improve and compare dissolution contour of poorly soluble BCS Class II drug Glimepirid...
Abdul Basit, Musarrat Riaz, Asher FawwadDepartment of Medicine, Baqai Institute of Diabetology and E...
Objective: In our study, the objective was to evaluate the effectiveness of glycemic control of Glim...
<p>Glimepiride (GMP) is an oral antidiabetic drug classified as BCS class II, demonstrating ex...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharm...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
Glimepiride is an antidiabetic agent used for lowering blood glucose levels. It induces the activity...
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator ...
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator ...
Background: Glimepiride (HOE490, AmarylR) is a new, third generation sulfonylurea, which binds to a ...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categor...
Background: Diabetes mellitus is a major public health problem with many complications. The Global B...
Objective: To improve and compare dissolution contour of poorly soluble BCS Class II drug Glimepirid...
Abdul Basit, Musarrat Riaz, Asher FawwadDepartment of Medicine, Baqai Institute of Diabetology and E...
Objective: In our study, the objective was to evaluate the effectiveness of glycemic control of Glim...
<p>Glimepiride (GMP) is an oral antidiabetic drug classified as BCS class II, demonstrating ex...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharm...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...